NOVO NORDISK INC. for NOVO NORDISK INC.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 1st Quarter - Report | Apr 18, 2016 | $910,000 | Replaced |
| 1st Quarter - Amendment (this page) | Apr 21, 2016 | $970,000 | Yes |
What was lobbied
8 issue areas, each in the filer's own words, with who lobbied on it and where.
Trade (domestic/foreign) TRD
P.L. 114-26 Bipartisan Congressional Trade Priorities and Accountability Act of 2015; EU/US Transatlantic Trade and Investment Partnership (TTIP) (intellectual property, regulatory harmonization)
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRIAN BRANTON | — |
| TRICIA BROOKS | — |
| AMANDA MAKKI | US Senator Lisa Murkowski (R-AK) |
| SARAH ELIZABETH NORDSTROM | — |
| LAUREN ELIZABETH SEMENIUK | — |
| AMY WOTRING | — |
Defense DEF
Issues related to TRICARE pharmacy benefit in FY17 National Defense Authorization Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRIAN BRANTON | — |
| TRICIA BROOKS | — |
| AMANDA MAKKI | US Senator Lisa Murkowski (R-AK) |
| SARAH ELIZABETH NORDSTROM | — |
| LAUREN ELIZABETH SEMENIUK | — |
| AMY WOTRING | — |
Taxation/Internal Revenue Code TAX
Protecting Americans from Tax Hikes Act of 2015(PATH) provision of P.L. 114-113 FY16 Consolidated Appropriations; H.R. 880 R&D tax credit; corporate tax inversion generally and in amendments to S.Con.Res.11 FY16 Senate Budget Resolution and S. 1376 FY16 National Defense Authorization Act; interest deductibility IRC 163(j)
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRIAN BRANTON | — |
| TRICIA BROOKS | — |
| AMANDA MAKKI | US Senator Lisa Murkowski (R-AK) |
| SARAH ELIZABETH NORDSTROM | — |
| LAUREN ELIZABETH SEMENIUK | — |
| AMY WOTRING | — |
Health Issues HCR
National Diabetes Prevention Program; Better care and treatment of people with diabetes under P.L. 111-148 Patient Protection and Affordable Care Act of 2009 (ACA) and P.L. 111-152 The Health Care & Education Affordability Reconciliation Act of 2010: Issues related to diabetes generally, and specifically diabetes screening, medical education and death certificate reporting (Catalyst for Better Diabetes), AHRQ and USPSTF diabetes screening standards; diabetes issues in Healthy People 2020 and the Office of Disease Prevention and Health Promotion (ODPHP); H.R. 1192 and S. 586 National Diabetes Clinical Care Commission Act of 2015; P.L. 114-10, Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) for Special Diabetes Program, CHIP, and childhood obesity; S. 84 and H.R. 3658 Gestational Diabetes Act of 2015; H.R. 1190 and S. 141 Protecting Seniors' Access to Medicare Act of 2015 (IPAB repeal); H.R. 2651 Eliminating Disparities in Diabetes Prevention, Access, and Care Act of 2015 (EDDPAC); cost of diabetes generally; S. 320 and H.R. 744 Medical Innovation Act of 2015; S. 2023 and H.R. 3513 Prescription Drug Affordability Act of 2015; H.R. 3742, Access to Marketplace Insurance Act and general allowance for certain third party payments of cost sharing; Congressional recognition of World Hemophilia Day
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRIAN BRANTON | — |
| TRICIA BROOKS | — |
| AMANDA MAKKI | US Senator Lisa Murkowski (R-AK) |
| SARAH ELIZABETH NORDSTROM | — |
| LAUREN ELIZABETH SEMENIUK | — |
| AMY WOTRING | — |
Medicare/Medicaid MMM
Issues related to Medicare Part D, Special Diabetes Program, CHIP, and childhood obesity in P.L. 114-10 Medicare Access and CHIP Reauthorization Act of 2015 (MACRA); H.R. 2102 and S.1131 Medicare Diabetes Prevention Act; H.R. 2404 and S. 1509 Treat and Reduce Obesity Act; Issues related to medical nutrition therapy services to such beneficiaries with pre-diabetes or with risk factors for developing type 2 diabetes H.R. 1686 Medical Nutrition Therapy 2015; issues related to patient diabetes education in H.R. 1726 Access to Quality Diabetes Education Act of 2015; Continuous Glucose Monitoring (CGM); Medicare diabetes screening generally; H.R. 1021 Protecting the Integrity of Medicare Act (PIMA) of 2015; H.R.2005 and S. 1083 Medicare Drug Savings Act of 2015; Physician Quality and Reporting System (PQRS)
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRIAN BRANTON | — |
| TRICIA BROOKS | — |
| AMANDA MAKKI | US Senator Lisa Murkowski (R-AK) |
| SARAH ELIZABETH NORDSTROM | — |
| LAUREN ELIZABETH SEMENIUK | — |
| AMY WOTRING | — |
Budget/Appropriations BUD
Issues related to National Diabetes Prevention Program in FY17 Labor/HHS/Education Appropriations, P.L. 114-113 FY16 Consolidated Appropriations, and P.L. 113-235 FY15 Consolidated and Continuing Appropriations; Issues related to Medicare Part D, FDA, patents, and federal procurement in S.Con.Res.11 FY16 Senate Budget Resolution and H.Con.Res.27 House Budget Resolution; H.R. 3660 Preventive Health Savings Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRIAN BRANTON | — |
| TRICIA BROOKS | — |
| AMANDA MAKKI | US Senator Lisa Murkowski (R-AK) |
| SARAH ELIZABETH NORDSTROM | — |
| LAUREN ELIZABETH SEMENIUK | — |
| AMY WOTRING | — |
Pharmacy PHA
P.L. 113-54 Drug Quality and Security Act (track and trace supply chain provisions); issues regarding biosimilars; issues regarding 340B; H.R.6 21st Century Cures Act; FDA in HR 3049 FY16 Agriculture Appropriations
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRIAN BRANTON | — |
| TRICIA BROOKS | — |
| AMANDA MAKKI | US Senator Lisa Murkowski (R-AK) |
| SARAH ELIZABETH NORDSTROM | — |
| LAUREN ELIZABETH SEMENIUK | — |
| AMY WOTRING | — |
Copyright/Patent/Trademark CPT
H.R. 9 Innovation Act and and S. 1137 PATENT Act (patent litigation and assertion); S.1890 and H.R.3326 Defend Trade Secrets Act of 2015
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRIAN BRANTON | — |
| TRICIA BROOKS | — |
| AMANDA MAKKI | US Senator Lisa Murkowski (R-AK) |
| SARAH ELIZABETH NORDSTROM | — |
| LAUREN ELIZABETH SEMENIUK | — |
| AMY WOTRING | — |
Foreign entities
Foreign owners and affiliates the filer disclosed. Amounts are as declared on this filing.
| Entity | Country | Principal place of business | Ownership | Contribution declared |
|---|---|---|---|---|
| REGISTRANT IS A WHOLLY-OWNED SUBSIDIARY OF NOVO NORDISK US WHICH IS WHOLLY OWNED BY NOVO NORDISK A/S. | Denmark | Denmark | 100.0% | — |
| NOVO A/S (OWNS 26.5% OF NN A/S) | Denmark | Denmark | 26.5% | — |
| NOVO NORDISK FONDEN (ULTIMATE PARENT COMPANY) | Denmark | Denmark | 100.0% | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.